AI Earnings Predictions for Serina Therapeutics Inc. (SER)

EX-99.1

2 ser-20260514xex991_earning.htm

EX-99.1

Document

Exhibit 99.1

Serina Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

–Phase 1b Registrational Clinical Study of SER-252 Underway in Advanced Parkinson’s Disease; TFL data from the SAD study arm targeted for first half of 2027 -

–Closed $21.2 million private placement financing to support continued advancement of SER-252 -

HUNTSVILLE, May 14, 2026 (GLOBE NEWSWIRE) — Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today reported its financial results for the first quarter ended March 31, 2026, along with key business updates.

“With our Phase 1b registrational study of SER-252 now underway and a strengthened balance sheet, Serina is entering an important execution phase as we work toward our first clinical data in patients with advanced Parkinson’s disease,” said Steve Ledger, Chief Executive Officer of Serina. “SER-252 represents the first clinical validation of our POZ Platform™, which is designed to optimize well-understood therapeutics by improving pharmacokinetics, tolerability and dosing profiles. We believe this approach has the potential to unlock meaningful value across multiple modalities, and we are building a pipeline and partnership strategy to fully leverage the breadth of the platform.”

•SER-252 Phase 1b Registrational Clinical Study: Following dosing of the first patient in February 2026, Serina continues to advance its Phase 1b registrational clinical study of SER-252 in advanced Parkinson’s disease. The Company anticipates completing enrollment and dosing of Cohort 1 by the end of the third quarter of 2026 and is targeting availability of TFL data from the SAD study arm in the first half of 2027.

•Closed Private Placement Financing: In March and April 2026, Serina closed the previously announced private placement of common stock, redeemable warrants and pre-funded warrants, resulting in aggregate gross proceeds of $21.2 million ("March 2026 PIPE"). In connection with the initial closing, the Senior Unsecured Convertible Promissory Note entered into on September 9, 2025 was amended to remove any further obligations to borrow or loan funds under the note. The closing also satisfied the requirements for the automatic conversion of all outstanding shares of Series A Preferred Stock, together with any accrued but unissued PIK Shares, into shares of Serina common stock.

First Quarter Operating Results

Operating expenses: Operating expenses for the three months ended March 31, 2026 and 2025 were $6.3 million and $5.9 million, respectively.

Research and Development (R&D) Expenses: R&D expenses were $3.2 million for the three months ended March 31, 2026, compared to $3.0 million for the same period in 2025.

General and Administrative Expenses: General and administrative expenses were $3.1 million for the three months ended March 31, 2026, compared to $2.9 million for the same period in 2025.

Other Expense, Net: Other expense was $0.6 million for the three months ended March 31, 2026 compared to $1.0 million other income for the same period in 2025. The $1.6 million increase in expenses was primarily attributable to a non-cash loss on extinguishment of financial commitment assets and contingent warrants from the amendment of the Senior Unsecured Convertible Promissory Note in connection with the March 2026 PIPE.

Net Loss: The net loss attributable to Serina for the three months ended March 31, 2026 was $6.9 million, or $(0.58) per basic and diluted share, compared to net loss of $4.8 million, or $(0.49) per basic and diluted share for 2025.

Cash and cash equivalents totaled $24.5 million as of March 31, 2026. In addition, gross proceeds of $5.2 million were received in April 2026 from the March 2026 PIPE.

About Serina Therapeutics

Serina is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. Serina’s POZ PlatformTM provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Serina is headquartered in Huntsville, Alabama on the campus of the HudsonAlpha Institute of Biotechnology.

About the POZ Platform™

Serina’s proprietary POZ technology is based on a synthetic, water soluble, low viscosity polymer called poly(2-oxazoline). Serina’s POZ technology is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered via subcutaneous injection. The therapeutic agents in Serina’s product candidates are typically well-understood and marketed drugs that are effective but are limited by pharmacokinetic profiles that can include toxicity, side effects and short half-l

EX-99.1

2 ser-20260323xex991_earning.htm

EX-99.1

Document

Exhibit 99.1

Serina Therapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights

- FDA Grants IND Clearance for SER-252

- SER-252 Phase 1b Trial Initiated

- Closed Private Placement Financing of up to $30 Million

HUNTSVILLE, March 25, 2026 (GLOBE NEWSWIRE) — Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today reported its financial results for the full year ended December 31, 2025 and provided recent business highlights.

"This past year was defined by execution, advancing SER-252 from IND filing through FDA clearance, into the clinic while strengthening our balance sheet to support the clinical milestones ahead," said Steve Ledger, CEO of Serina. "With the first patient dosed in our registrational trial in advanced Parkinson's disease, and up to $30 million in new financing now secured, Serina enters 2026 with the clinical and financial foundation to reach meaningful value-creating inflection points. We are grateful to Dr. Greg Bailey for leading this financing and stepping into the role of Co-Chairman alongside Dr. Simba Gill. His commitment to SER-252 and the broader POZ platform opportunity and extensive experience guiding biotechnology companies make him an exceptional partner as we advance this program."

Recent Highlights

•FDA Grants IND Clearance for SER-252; Phase 1b Trial Initiated: In January 2026, Serina announced the U.S. Food and Drug Administration (FDA) had cleared the Investigational New Drug (IND) application for its lead product, SER-252, for the treatment of advanced Parkinson's disease. In February 2026, the Company enrolled and dosed its first patient in its Phase 1 registrational trial evaluation SER-252.

•Private Placement Financing of up to $30 Million: On March 17, 2026, Serina entered into definitive agreements for the private placement of common stock and pre-funded warrants to raise at least an initial aggregate of $15 million in gross proceeds, with one or more additional closings for aggregate gross proceeds of at least $5.0 million and up to $15.0 million to be funded within 20 days after the initial closing. The financing structure includes 50% warrant coverage to provide additional potential proceeds of up to $33.3 million from the future exercise of warrants. The transaction was led by Greg Bailey, M.D., who will assume the role of Co-Chairman of the Board alongside Simba Gill, Ph.D. In connection with the closing of the private placement, the Senior Unsecured Convertible Promissory Note previously entered on September 9, 2025, was amended to remove further obligations to borrow or loan funds under the note. As of March 23, 2026, gross proceeds of $16.0 million have been received.

•At-the-Market (ATM) Equity Program: In April 2025, Serina entered into a Capital on Demand™ Sales Agreement with JonesTrading Institutional Services LLC, under which the Company may offer and sell up to $13.3 million of common stock. Thus far in 2026, we sold 3.0 million shares of common stock at an gross average price of $3.36, resulting in gross proceeds of $10.0 million. To date, Serina has issued 3.5 million shares of common stock under the ATM program at a gross average per share price of $3.72, resulting in gross proceeds of $12.9 million.

Annual 2025 Operating Results

Operating expenses: Operating expenses for the years ended December 31, 2025 and 2024 were $24.2 million and $17.1 million, respectively.

Research and Development (R&D) Expenses: Research and development expenses were $13.2 million for the year ended December 31, 2025, compared to $7.5 million for the same period in 2024. The increase of $5.7 million was primarily due to increases in clinical related activities, compensation as a result of increased headcount, consultant spend for research programs, amortization of a prepaid technology access fee, and increased spend in outsourced research services. These increases were primarily offset by a decrease in severance and related costs.

General and Administrative Expenses: General and administrative expenses were $11.0 million for the year ended December 31, 2025, compared to $9.6 million for the same period in 2024. The increase of $1.4 million is due primarily to increases in stock based compensation expense as a result of new hires and directors, consulting expenses for public company infrastructure and investor outreach activities. These increases were primarily offset by decreases in legal fees and professional fees for the maintenance of certain patent and other intellectual property included in Legacy Assets and decreases in severance and related costs.

Other Income, Net: Other income, net was $4.8 million for the year ended December 31, 2025, compared to $5.8 million for the same period in 2024. The $1.0 million decrease is primarily attr

EX-99.1

2 ser-20251113xex991_earning.htm

EX-99.1

Document

Exhibit 99.1

Serina Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights

HUNTSVILLE, November 13, 2025 (GLOBE NEWSWIRE) — Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE American: SER), a clinical-stage biotechnology company advancing its lead Investigational New Drug ("IND") candidate, SER-252, for advanced Parkinson's disease, enabled by its proprietary POZ Platform™ drug optimization technology, today announced its financial results for the third quarter ended September 30, 2025, along with key recent updates.

Steve Ledger, Chief Executive Officer of Serina, stated, "The FDA's alignment with our plan to advance SER-252 under a 505(b)(2) NDA pathway, and its recognition of the Phase 1b trial as registrational, represents a key milestone for Serina. This outcome underscores our regulatory and development strategy, positioning SER-252 for an accelerated path to potential approval. It also highlights the broader opportunity for our POZ platform to streamline development timelines and unlock significant value across our pipeline."

•Regulatory Update: SER-252 for Advanced Parkinson’s Disease: Following a Type B meeting with the U.S. Food and Drug Administration (the "FDA") in August 2025, the FDA's written feedback supported Serina’s proposal to advance SER-252 under a 505(b)(2) NDA pathway for advanced Parkinson’s disease. On November 3, 2025, the FDA placed the IND on clinical hold pending additional information regarding a commonly used formulation excipient. The hold does not relate to the active drug substance or its mechanism of action. Serina expects the formal FDA communication within 30 days and is actively working to address the FDA’s questions to enable the initiation of the registrational study as soon as possible.

•Advancement of SER-270 for Tardive Dyskinesia: Serina continues to advance SER-270, its next program from the POZ Platform, designed to deliver long-acting VMAT2 inhibition for the treatment of tardive dyskinesia (TD). The Company is on track to complete formulation optimization and pre-IND activities in 2026.

•Secured Up to $20 Million in Funding: In September 2025, Serina entered into a convertible note and warrant financing agreement providing up to $20 million in funding, led by a member of Serina’s Board of Directors. The first $5 million tranche was drawn in September. If all warrants are issued and exercised in full, the financing could yield additional gross proceeds of up to $20 million.

•Expanded Stakeholder Communications and Transparency Initiatives: In October 2025, Serina launched a comprehensive corporate communications platform to enhance stakeholder engagement and transparency. The initiative includes regular digital updates, educational content, multimedia resources, and expert commentary aimed at patients, clinicians, investors, and the scientific community.

•At-the-Market (ATM) Equity Program: In April 2025, Serina entered into a Capital on Demand™ Sales Agreement with JonesTrading Institutional Services LLC, under which the Company may offer and sell up to $13.3 million of common stock. As of November 7, 2025, Serina has issued 474,712 shares of common stock at a gross average price of $6.00, resulting in net proceeds of $2.8 million.

Third Quarter Operating Results

Operating Expenses: Operating expenses for the three months ended September 30, 2025 and 2024 were $6.4 million and $5.3 million, respectively.

Research and Development (R&D) Expenses: R&D expenses were $3.6 million for the three months ended September 30, 2025, compared to $2.4 million for the same period in 2024. The increase of $1.2 million is primarily driven by increases in outsourced research services, consultant spend mainly for chemistry, manufacturing, and controls activities, amortization for a prepaid technology access fee and increased spend in clinical related activities. These increases were partially offset by decreases in legal patent fees for certain patent and other intellectual property and biological material assets included in Legacy Assets and salaries.

General and Administrative Expenses: General and administrative expenses were $2.7 million for the three months ended September 30, 2025, compared to $2.9 million for the same period in 2024. The net decrease of $0.2 million is due to the reduction of compensation related costs partially offset by an increase in investor outreach expenses.

Other Income, Net: Other income was $1.8 million for the three months ended September 30, 2025 compared to $6.7 million net income for the same period in 2024. The $4.9 million net decrease in income was primarily attributable to the change in fair value of liability classified warrants partially offset by a gain in warrant expirations.

Net (Loss) Income: The net loss attributable to Serina for the three months ended September 30, 2025 was $4.6 million, or $0.45 per basic and